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Single IRBs inMultisite Trials
Questions Posed by the NewNIH Policy
On June 21, 2016, the US government announced
changes that are arguably themost significantof the last
quarter century concerning the protection of human
research participants—a requirement for use of central
or single institutional review boards (IRBs) in multisite
National Institutes of Health (NIH)–funded research.
Specifically, the NIH announced a new policy (effective
September25, 2017) tomandate thatnonexemptmulti-
siteresearchwithhumansfundedbytheNIHbereviewed
byasingle IRB.1OnJanuary19,2017, finalamendmentsto
the federal human researchparticipant protection regu-
lations(theCommonRule)werealsopublished, requiring
useof a single IRB,2 although implementationwill bede-
layed until January 20, 2020. The NIH directive seems
straightforward,buteffective implementationwill require
that institutions, researchers, and policy makers decide
howtoaddress anumberof critical issues. TheCommon
Rule amendments explicitly recognize that further guid-
ancewill need tobedeveloped, necessitating that these
stakeholders confront several dilemmas.2
UnderlyingtheNIHsingle-IRBpolicy is thebelief that
the use of single IRBs formultisite studies avoids dupli-
cate and possibly conflicting IRB reviews and thereby
streamlines and accelerates the review process. Stud-
ies of local IRBs have been conducted,3,4 but research
data supporting thebenefits of single IRBsand informa-
tion on how they operate and the difficulties they face
remain very limited, adding to these challenges.
Ofall theissuesraisedbytheNIHsingle-IRBpolicy,the
relationshipbetweenthesingle IRBandtheparticipating
sites ispossibly themost complex.Thereare3critical as-
pects that academic institutions, researchers, andpolicy
makerswillhavetoresolvebefore implementationof the
newpolicy: (1) therelationshipbetweenthesingle IRBand
the local institutions, including the local IRBs; (2) the col-
lectionandincorporationof localknowledge inthesingle-
IRBreview;and(3)therelationshipbetweenthesingleIRB
and local researchers. These issues involve fundamental
legal,ethical, institutional,andpolicytensionsthatwillpro-
foundly shape the costs andeffectivenessof futuremul-
tisite research involving human research participants.
Relationship Between the Single and Local IRBs
The NIH single-IRB policy outlines responsibilities be-
tween single and local IRBs that will apply only to NIH-
funded research as of September 25, 2017, and similarly
to all research with humans, through the changes to the
CommonRule,asofJanuary20,2020.Single IRBswillbe
expected to carry out the ethical reviewof the study and
thefunctionsrequiredforinstitutionalcompliancewiththe
CommonRule;whereas local IRBswill be responsible for
meeting other regulatory obligations, overseeing imple-
mentationof theapprovedprotocol,andreportingunan-
ticipatedproblems.However, thesingleandthe local IRBs
both retain regulatory responsibilities. Separation be-
tween the more formal Common Rule–required regula-
toryfunctionsandthelocalresponsibilitiesassociatedwith
broaderprotectionsof research involvinghumans(eg, re-
porting unanticipated problems, managing investiga-
tors’ and institutional conflicts of interest, ensuring train-
ing inresearchethics,anddealingwithnoncompliance) is
not clearly differentiated.Decisionswill need tobemade
regarding which responsibilities will be shared, how re-
sponsibilities will be determined, and how conflicts be-
tween the single and local IRBswill be resolved.
It isalsounclearwhether local IRBswillhaveinput into
single-IRB reviews, and if so, atwhat stage, andwhowill
have the final say. What if the local IRB disagrees with
the single IRB?TheCommonRule amendments indicate
that institutions may still conduct additional local-IRB
reviews,butsuchreviews“wouldnolongerhaveanyregu-
latory status.”2 What this means and how such reviews
might affect single-IRB reviews are uncertain.
Local IRBsandthe institutionstheyrepresentwilluse
reliance (or authorization) agreements, which cede re-
view of research to the single IRB and its larger institu-
tion. These reliance agreementswill need toaddress the
aforementioned issuesbutcurrentlyvarygreatly inscope
andcontent—often toaccount for thepractical concerns
of the relying institutions, the needs of specific studies,
and single IRBs’ concerns about risks and attendant li-
abilities. Few standardized models of reliance agree-
mentsexist.Yetwith limitedmodels, thenegotiationwith
multiple sites could take as much or more time as mul-
tiple local-IRBreviews.Anationalmodelortemplatemight
help, but whether one such agreement couldworkwith
all types of research and research institutions is unclear.
Recently, the NIH National Center for Advancing
Translational Sciences proposed use of a single master
reliance agreement that canbeused across institutions
andstudies (SMART IRBplatform).5 This relianceagree-
ment allows for flexibility among theparticipating insti-
tutions and leaves the specifics ofmany issues tobede-
termined on a study-by-study or protocol-by-protocol
basis. However, few data exist on how the agreement
would be used nationally.
Collection and Incorporation of Local Knowledge
Many issues in IRB reviews reflect state or local laws, in-
stitutional policies and resources, information about lo-
cal medical standards of care, investigators’ past experi-
ences, and the demographics and vulnerabilities of the
local study populations. These issues may involve small
details in standards of care practices or the circum-
stances inwhichpotential researchparticipantscanbeap-
proachedforconsenttoparticipate inresearch.Single-IRB
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members are likely to be unaware of these kinds of information that
local IRBmembers routinelyacquire in their clinicalor researchwork.
EventhoughthenewNIHregulationsstatethatparticipatingsites
areexpectedtocommunicate“relevant informationnecessaryfor the
single IRB to consider local context issues and state and local regula-
toryrequirements,”2thisformulationisvagueandrequiresmorespeci-
fication. Delineation of the typeof information that single IRBs need
to have, development of mechanisms to collect and transmit local
knowledgeeffectively andefficiently, and clarificationof the roles of
such contextual information in single-IRB reviews are critical.
Relationships Between the Single IRB and Local Researchers
Another issue that will need to be addressed is how single IRBswill
replace the ongoing relationships and close interactions thatmany
local IRBs have with local researchers. Currently, local-IRB mem-
bers and local investigators often know each other well, enabling
curbside consults and hallway conversations that help investiga-
tors understand IRB concerns and also help IRBs to appreciate in-
vestigators’needsandconstraints.Visitsby investigators to local IRB
offices can often resolve questions and facilitate protocol reviews.
Removing reviews to a remote single IRB is likely to reduceor elimi-
nate these important informal interactionsandpossibly increase the
time needed to approve research. If these interactions are valu-
able, consideration should be given to how they could be incorpo-
rated into the single-IRB model without diluting the potential effi-
ciencies of centralized review.
Will single IRBsoffer thekindofprospectivehelp in craftingpro-
tocols that local IRBs often provide—interactions that may not al-
ways be most efficiently handled through formal mechanisms?
Will single IRBshavemechanisms for responding to investigators’ re-
quests for individualized assistance regarding IRB concerns post
review? If so, what kinds of mechanisms? Will investigators only be
able to interact with the single IRB through their local IRB, and if so,
will thischangeentailpossibleadditionaldelays?Bestpracticesshould
be developed to support single IRBs’ interactions with investigators
(eg, scheduled times for teleconferencesbetween investigators and
the single IRB; hotlines or other communication mechanisms). De-
veloping,assessing,andimplementingbestpracticeswillpreventeach
single IRB fromhaving to reinvent thesemeasures.Researchersmay
also facemany expectations and demands from various single IRBs,
including required use of different information technology plat-
forms, and need to provide different types of information. Develop-
ment ofworkable communication practices could help preempt fur-
ther complications and delays in protocol reviews.
Implications for a System of Single-IRB Review
If the complexities and burdens of serving as a single IRB become
toogreat foracademicorothernonprofit institutions, theNIHpolicy
could result in a substantial increase in the number of studies being
reviewedby for-profit IRBs,whichmay currently have themost ex-
perience serving as the IRB inmultisite studies. Critics have argued
that for-profit IRBs may emphasize speed rather than thorough-
ness of review.6,7 Large for-profit IRBsmay do an excellent job, but
nopublisheddatahavebeenfoundregardingtheirprocedures,qual-
ity, or effectiveness, and they may be resistant to undergoing out-
side examination.
In addition, theNIHhas recognized thatno systemwillwork for
all circumstances, and it has acknowledged the need for excep-
tions to the single-IRB requirement. TheNIHstated that itwillmake
exceptions if a “compelling justification”exists,2but itdidnot specify
the standards or circumstances for such exceptions. The Common
Ruleamendmentsalsopermit a federaldepartmentoragency tode-
terminethatsingle IRBsarenotappropriate forcertaincontexts,per-
mitting local IRB reviewwith local variations, but again, the specific
criteria to be applied are unstated.
In summary, although the NIH single-IRB policy is designed to
improve IRB review of multisite studies by accelerating the review
process, given the number of public comments that were gener-
ated prior to the policy being finalized and the fact that the policy
has been developed in the absence of the systematic collection of
data, significant issues remain unresolved. These obstacles are not
insurmountable,but theNIH,academic institutions, researchers,and
others should begin to consider how best to address these chal-
lenges.Data regarding theprocessandoutcomesofasingle-IRBsys-
tem should be collected and analyzed to formulate best practices
fordefining therelationshipsandboundariesbetween local IRBsand
single IRBs, developing standardized ways for single IRBs to ac-
count for local practices, andestablishingworking relationshipsbe-
tween single IRBs and investigators. Appropriate implementation
of theNIHsingle-IRBpolicywill be key todevelopinganefficient re-
search-friendly process for multisite IRB reviews that continues to
ensure the protection of human research participants.
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